- If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell
- Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps
Regeneron Pharmaceuticals And Sanof's Dupixent (Dupilumab) SBLA Accepted For FDA Priority Review For Treatment Of Adolescents With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.